Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Ian B, Walters"'
Autor:
Philippe Bedard, Lillian L Siu, Jacob Thomas, Diana Hanna, Anthony J Olszanski, Nilofer Azad, Giles Whalen, Matthew Ingham, Syed Mahmood, Lewis H Bender, Ian B Walters, Anthony El-Khoueiry
Publikováno v:
Cancer Research. 82:P5-16
Background: INT230-6 is a novel formulation of cisplatin and vinblastine with an amphiphilic cell penetration enhancer that has been shown to enhance dispersion of the drug throughout tumors and allow diffusion into cells when given intratumorally. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f3b8fe49947197cebfc3b0d4b90acac
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-13
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-13
Purpose: Preclinical trials of a mouse model of pancreatic neuroendocrine tumors (PNET) were conducted to determine whether dual FGF/VEGF pathway inhibition with brivanib can improve first-line efficacy in comparison with VEGF inhibitors lacking fibr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1efd270c331302a028239c7ccf0956ea
https://doi.org/10.1158/1078-0432.c.6519612.v1
https://doi.org/10.1158/1078-0432.c.6519612.v1
CCR Translation for This Article from Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3433c49fc665c77217ef445fcf097f37
https://doi.org/10.1158/1078-0432.22443024
https://doi.org/10.1158/1078-0432.22443024
Autor:
Matthew Ingham, James S Hu, Giles Francis Whalen, Jacob Stephen Thomas, Anthony B. El-Khoueiry, Diana L. Hanna, Anthony J. Olszanski, Christian Frederick Meyer, Nilofer Saba Azad, Luis H. Camacho, Syed Mahmood, Lewis H. Bender, Ian B. Walters, Lillian L. Siu, Albiruni Ryan Abdul Razak
Publikováno v:
Journal of Clinical Oncology. 40:11515-11515
11515 Background: INT230-6 is a novel intratumoral (IT) agent with a dual anti-cancer mechanism (tumor cytoreduction while stimulating antigen presentation and recruitment of T-cells). The drug is comprised of cisplatin (CIS) and vinblastine (VIN) co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1da18a87d068bf9704604ff2a2df473b
https://doi.org/10.1200/jco.2022.40.16_suppl.11515
https://doi.org/10.1200/jco.2022.40.16_suppl.11515